KRAS and neoplasm: Najumudeen et al. (2021) found that SLC7A5, a glutamine antiporter, is a promising target for therapy-resistant KRAS-mutant CRC, as mutant KRAS changes the basal metabolism of the tumor, increasing glutamine consumption to enhance proliferation. Zhao et al. (2020) reported that the combination of glutaminase inhibitor CB-839 with capecitabine preferentially inhibits PIK3CA-mutant CRC.